Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ziprasidone: profile on safety.

P J Goodnick1

  • 1Department of Psychiatry & Behavioral Sciences, University of Miami School of Medicine, 1400 NW 10 Avenue, Ste 304A, Mail Code D79, Miami, Florida 33136, USA. pgoodnick@aol.com

Expert Opinion on Pharmacotherapy
|February 5, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Depression in the new millennium.

CNS spectrums·2008
Same author

Psychopharmacology of depression in the next millennium.

CNS spectrums·2008
Same author

Antipsychotic medication: effects on regulation of glucose and lipids.

Expert opinion on pharmacotherapy·2002
Same author

Rapid cycling bipolar disorder.

Expert opinion on pharmacotherapy·2002
Same author

Vagus nerve stimulation in depression.

Expert opinion on pharmacotherapy·2001
Same author

Use of antidepressants in treatment of comorbid diabetes mellitus and depression as well as in diabetic neuropathy.

Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists·2001
Same journal

Pharmacotherapeutic interventions for pediatric ulcerative colitis.

Expert opinion on pharmacotherapy·2026
Same journal

The rise and fall of TRPV1-targeted analgesia in osteoarthritis: a critical appraisal.

Expert opinion on pharmacotherapy·2026
Same journal

Dopamine transporter and beyond: evolving targets and combination strategies in stimulant use disorder.

Expert opinion on pharmacotherapy·2026
Same journal

GnRH antagonists for the treatment of fibroids and adenomyosis, current evidence and future perspectives.

Expert opinion on pharmacotherapy·2026
Same journal

Pharmacotherapeutic strategies for the management of congenital adrenal hyperplasia.

Expert opinion on pharmacotherapy·2026
Same journal

Current advances in pharmacotherapeutic strategies for the treatment of complicated intra-abdominal infections.

Expert opinion on pharmacotherapy·2026
See all related articles

Ziprasidone, an atypical antipsychotic, offers a unique receptor binding profile and neurotransmitter activity. It demonstrates a favorable safety profile with low adverse events, weight gain, and movement disorders, despite some ECG changes.

Area of Science:

  • Pharmacology
  • Neuroscience
  • Psychiatry

Background:

  • Ziprasidone is a novel atypical antipsychotic.
  • It belongs to a new class of antipsychotics, succeeding others like clozapine and risperidone.
  • Ziprasidone exhibits a high serotonin Type 2a/dopamine Type 2 (5-HT2a/D2) receptor binding ratio.

Purpose of the Study:

  • To detail the pharmacological profile of ziprasidone.
  • To explore the relationship between its receptor binding and clinical effects.
  • To assess its safety and tolerability profile.

Main Methods:

  • Analysis of ziprasidone's receptor binding affinities (5-HT2a/D2, 5-HT1aR, 5-HT1dR, 5-HT2cR, H1, alpha 1-adrenoceptors, M1).
  • Evaluation of its effects on neurotransmitter re-uptake (serotonin and noradrenaline).

Related Experiment Videos

  • Review of clinical data regarding adverse events, metabolic profile, and electrocardiogram (ECG) effects.

    • Main Results:

    • Ziprasidone has a high 5-HT2a/D2 binding ratio and acts as a 5-HT1aR agonist.
    • It blocks serotonin and noradrenaline re-uptake, with antagonist activity at 5-HT1dR and 5-HT2cR.
    • Low affinity for H1 and alpha 1-adrenoceptors, negligible for M1 receptors, correlates with low adverse events, minimal weight gain, and reduced movement disorders.
    • ECG data shows QTc interval changes but no associated mortality from overdoses or torsade de pointes.

    Conclusions:

    • Ziprasidone's unique pharmacological profile contributes to its favorable safety and tolerability.
    • It presents a low incidence of common antipsychotic side effects.
    • While QTc changes are noted, ziprasidone appears safe regarding serious cardiac events and mortality.